These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Westanmo AD; Gayken J; Haight R Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903 [TBL] [Abstract][Full Text] [Related]
26. Role of serotonin and noradrenaline in stress urinary incontinence. Michel MC; Peters SL BJU Int; 2004 Jul; 94 Suppl 1():23-30. PubMed ID: 15139860 [No Abstract] [Full Text] [Related]
27. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. Berk M; du Plessis AD; Birkett M; Richardt D Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869 [TBL] [Abstract][Full Text] [Related]
28. Serotonin-norepinephrine reuptake inhibitor treatment for tinnitus and depression. Chang JP; Wu CC J Clin Psychopharmacol; 2012 Oct; 32(5):729. PubMed ID: 22926618 [No Abstract] [Full Text] [Related]
29. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Mariappan P; Ballantyne Z; N'Dow JM; Alhasso AA Cochrane Database Syst Rev; 2005 Jul; (3):CD004742. PubMed ID: 16034945 [TBL] [Abstract][Full Text] [Related]
30. Successful duloxetine use to prevent venlafaxine withdrawal symptoms. Hsiao MC; Liu CY Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418 [No Abstract] [Full Text] [Related]
31. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants. Ashton AK; Longdon MC Am J Psychiatry; 2007 Jul; 164(7):1121-2. PubMed ID: 17606668 [No Abstract] [Full Text] [Related]
32. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844 [TBL] [Abstract][Full Text] [Related]
33. Improvement with duloxetine in an adult ADHD patient. Tourjman SV; Bilodeau M J Atten Disord; 2009 Jul; 13(1):95-6. PubMed ID: 19359667 [TBL] [Abstract][Full Text] [Related]
34. Duloxetine: a new selective and dual-acting antidepressant. Bauer M; Möller HJ; Schneider E Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814 [TBL] [Abstract][Full Text] [Related]
35. Duloxetine-modulating effects of brain structure in major depressive disorder with panic disorder. Lai CH J Clin Psychopharmacol; 2010 Feb; 30(1):88-9. PubMed ID: 20075662 [No Abstract] [Full Text] [Related]
36. Duloxetine: a review of its pharmacology and use in chronic pain management. Bellingham GA; Peng PW Reg Anesth Pain Med; 2010; 35(3):294-303. PubMed ID: 20921842 [TBL] [Abstract][Full Text] [Related]
37. [Physical recovery is part of remission]. Krankenpfl J; 2004; 42(3-4):110. PubMed ID: 15311907 [No Abstract] [Full Text] [Related]
38. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Thor KB Urology; 2003 Oct; 62(4 Suppl 1):3-9. PubMed ID: 14550831 [TBL] [Abstract][Full Text] [Related]